Pembrolizumab combined with chemotherapy then demonstrated a benefit over chemotherapy in the phase III clinical trials KEYNOTE-189 (for nonsqamous NSCLC) and KEYNOTE-407 (for squamous NSCLC), including patients with high PD-L1 expression 3, 4. Here, CD274 is linked to non-small cell lung carcinoma.